



You Don't Need Reproducible Research

UNTIL YOU DO.

If your work is successful in your lab, it should be successful on the other side of the world. That's why we engineer CO₂/O₂ incubators that deliver reproducible results, contamination free and equal to *in vivo* reality.

Minimize uncertainty
with PHCbi brand products



PHC Corporation of North America

PHC Corporation of North America
1300 Michael Drive, Suite A, Wood Dale, IL 60191
Toll Free USA (800) 858-8442, Fax (630) 238-0074
www.phchd.com/us/biomedical

phchd.com/us/biomedical/cell-culture-incubators

PHC Corporation of North America is a subsidiary of PHC Holdings Corporation, Tokyo, Japan, a global leader in development, design and manufacturing of laboratory equipment for biopharmaceutical, life sciences, academic, healthcare and government markets.

Life Science Innovator Since 1966

Christos Nakas ORCID iD: 0000-0003-4155-722X

Antibody Titers After a Third Dose of the SARS-CoV-2
BNT162b2 Vaccine in immunocompromised adults in
Greece: is a fourth dose necessary?

Konstantina Kontopoulou¹, Christos T Nakas^{2,3}, Chrysoula Belai¹, Georgios Papazisis^{4,5}

¹Laboratory of Microbiology, “G. Gennimatas” General Hospital, Thessaloniki, Greece,

²Laboratory of Biometry, University of Thessaly, Nea Ionia/Volos, Magnesia, Greece

³University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland

⁴Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece

⁵Clinical Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Greece

e-mails & ORCID: Konstantina Kontopoulou: ntinakont@yahoo.gr- ORCID: 0000-0003-0121-8688; Christos T Nakas: cnakas@uth.gr- ORCID:0000-0003-4155-722; Chrysoula Belai: xrisabelai@gmail.com; Georgios Papazisis: papazisg@auth.gr-ORCID: 0000-0003-1641-9095

Corresponding author

Georgios Papazisis, MD, PhD

Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Greece. e-mail:

papazisg@auth.gr

Author Contributions: K.K.: Conceptualization, project administration, investigation, writing—original draft; C.T.N.: methodology, formal analysis; C. Belai: project administration, investigation; G.P.: Conceptualization, supervision, writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding: none

Ethics approval statement: The study was approved by the ethics committee of the scientific council of the G. Gennimatas General Hospital (protocol number:1/13.1.2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: None.

Conflicts of Interest: The authors declare no conflict of interest.

Abstract:

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.27954.

This article is protected by copyright. All rights reserved.

Real-world data suggests that protection against COVID-19 declines a few months after vaccination, particularly in the elderly and immunocompromised individuals. Our study aimed to analyze the humoral response induced by a third supplemental dose of BNT162b2 vaccine in a mixed group of immunocompromised individuals by determining anti-spike (anti-S) IgG antibody titers at baseline (pre-third vaccine dose) and 4 weeks after the dose.

Serum samples were obtained from a total group of 85 immunocompromised individuals (history of cancer: n=20, lymphoma: n=4, leukemia: n=3, transplant recipients: n=4, autoimmune disease: n=42, inflammatory disease: n=6, autoimmune diabetes type 1: n=6) all of whom had previously received a two-dose schedule of the vaccine. The average number of days between 2nd and 3rd dose was 139.6145 (\pm 41.39071). The overall IgG GMCs four weeks post vaccination were increased by more than 35 times (fold change = 35.30, $p < 0.001$). Fold changes were not significantly correlated with underlying condition, age, sex nor with days between 2nd and 3rd dose.

Considering the predominance of omicron variants in the current period and the results of studies showing a decrease in the effectiveness of the 3rd dose after 10 weeks we highly recommend a fourth dose to this vulnerable population group.

Keywords: BNT162b2 mRNA COVID-19 vaccine; immunogenicity; antibody titers; immunocompromised adults; SARS-CoV-2; 3rd dose; Greece

Introduction

The rapid development and subsequent authorization of vaccines against SARS-CoV-2 has been an important step towards the management of the COVID-19 pandemic.¹ The efficacy of the vaccines administered so far is beyond doubt managing to reduce, fundamentally, the severe forms of the COVID-19 disease and hence the mortality worldwide. Nevertheless, real-world data suggested that the humoral immune response and protection against SARS-CoV-2 infection and disease seem to be declining a few months after vaccination, particularly in the elderly and immunocompromised individuals.²

Immunocompromised people, like those with solid or haematological malignancies, hematopoietic stem cell transplantation and those with autoimmune diseases or receiving immunosuppressive drugs, are among those most susceptible to COVID-19 infection. Studies indicate a reduced antibody response in immunocompromised people following a primary vaccine series, compared to

healthy vaccine recipients.^{3,4} Observation of SARS-CoV-2-specific immune response in individuals with defined immunodeficiencies revealed that defects in humoral immunity have been associated with incomplete immune control of SARS-CoV-2, prolonged viral culture and shedding.⁵ In addition, studies have shown that patients requiring immunosuppressive treatment for autoimmune and inflammatory rheumatic diseases have worse outcomes from COVID-19 compared with patients without such conditions.⁶

Finally, it is worth mentioning, that immunocompromised people are more likely to develop breakthrough infections. Since 40% of hospitalized breakthrough cases are immunocompromised people⁷ to minimize the risk of COVID-19 breakthrough infections among vaccinated immunocompromised people, many countries prioritized this group to receive an additional vaccine dose. The Greek Ministry of Health announced a deployment plan in early autumn, in order to administer a third dose of the BNT162b2 mRNA COVID-19 vaccine, starting with immunocompromised patients on September 15, 2021. The third dose was only given to people who had received the second dose at least 3 months before.

Immune responses following SARS-CoV-2 additional doses vaccination, have not been adequately studied in potentially immune vulnerable patient groups. This study aimed to analyze the humoral response induced by a third supplemental dose of BNT162b2 vaccine in a mixed group of immunocompromised individuals by determining anti-spike (anti-S) IgG antibody titers at baseline (pre-third vaccine dose) and 4 weeks post third BNT162b2 additional dose.

Material – Methods

Serum samples were obtained from a total group of 85 immunocompromised individuals all of whom had previously received a two-dose schedule of the vaccine with a three-week dosing interval. In particular, on the day of the third vaccination, blood was drawn, prior to administration of the additional dose, for baseline serology assessment of receptor-binding domain (RBD) IgG antibodies titers. Four weeks following the third dose, testing for RBD IgG titers, was repeated to assess the humoral response to the vaccine. The participants were classified into two groups. In the first group (n=31), patients with a history of solid organ or hematologic cancers and recipients of hematopoietic cell or solid organs transplant were included. (History of cancer: n=20, lymphoma: n=4, leukemia: n=3, transplant recipients: n=4). The second group (n=54) composed of

patients with autoimmune diseases or patients under immunosuppressive therapy (Autoimmune disease: n=42, Inflammatory disease: n=6, autoimmune diabetes type 1: n=6). Written informed consent was obtained from all participants. Approval of the study protocol was obtained by the ethics committee of the scientific council of the G. Gennimatas General Hospital (protocol number:1/13.1.2021), in accordance with the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice.

Titers of total RBD-specific IgGs against SARS-CoV-2 were determined using the SARS-CoV-2 IgG II Quant assay on the ARCHITECT System (SARS-CoV-2 IgG II Quant, Abbott Sligo, Ireland) on participant-derived serum samples. The SARS-CoV-2 IgG II Quant assay is used to monitor antibody response in individuals that have received the COVID-19 vaccine, by quantitatively measuring IgG antibodies against the spike RBD of SARS-CoV-2.

The geometric mean concentration (GMC) and respective 95% confidence intervals were calculated based on the recorded antibody concentration values.

RT-PCR was performed on seven participants who became infected with SARS-CoV-2, two to five months after the 3rd dose vaccination, found positive by the Allplex™ SARS-CoV-2 Master Assay (Seegene Inc. Taewon Bldg.91, Ogeum-ro, Songpa-gu, Seoul, 05548, Korea).

PCR was performed with a CFX96- Dx Touch Real-Time PCR Detection System (Bio-Rad, USA) and results were analysed with Seegene Viewer V1.0 software (Seegene). Furthermore, detection of Omicron variant (B.1.1.529) was achieved, using Allplex™ SARS-CoV-2 Variants I Assay (HV69/ 70del E484K N501Y – spike variants) and Allplex™ SARS-CoV-2 Variants II Assay (W152C L452R K417N K417T-spike mutations) (Seegene Inc. Taewon Bldg.91, Ogeum-ro, Songpa-gu, Seoul, 05548, Korea).

The participants were encouraged to fill and submit spontaneously to the Greek regulatory agency for medicines (EOF) the Individual Case Safety Report (ICSR) form for any suspect adverse event, especially the SAEs (serious adverse events) and the SUSARs (suspected unexpected serious adverse events).

Descriptive statistics were based on geometric means of concentrations (GMC) of anti-SARS-COV-2 spike IgG (AU/ml) and the corresponding 95% confidence intervals by groups of interest (group 1 and 2, gender, COVID-19 infection after 3rd dose). Independent samples t tests were used for the assessment of differences

of log₁₀ IgG levels for two group means comparisons. Correlation analysis was performed for the study of linear relationships between continuous variables of interest (fold changes due to booster dose, age, days between 2nd and 3rd dose). Stata 16.1 (Stata Corp. LLC, College Station, TX) was used for data analysis.

RESULTS

Our study included 85 vulnerable participants whose anti-RBD IgG titers were determined just before and one month after the third dose administration. Among them, 39 (45.9%) were male with a mean age of 62.72±13.16 years. The average number of days between 2nd and 3rd dose was 139.6145 (±41.39071).

At baseline, the measured levels of IgG GMC, were 363.87 (185.38, 714.22) AU/ml in the 1st group, which then increased after the 3rd dose to 12874.01 (9106.99, 18199.2) and the correspondents of the 2nd group were 437.38 (308.09, 620.93) at baseline and 17430.22 (14690.71, 20680.6) after the additional dose. The overall IgG GMCs four weeks post vaccination compared to those pre 3rd dose value, were increased by more than 35 times (fold change = 35.30, p<0.001) (**Table 1**). After the 3rd booster dose, there were non-significant differences between the two groups (p=0.338) (**Figure 1**). Furthermore, fold changes were not significantly correlated with age (r=0.013, p=0.908) nor with days between 2nd and 3rd dose (r=0.167, p=0.131) (**Figure 2**). Only seven subjects were infected with the Omicron variant (B.1.1.529) two to five months after the third dose. All of the patients with subsequent COVID-19 infection, developed only mild disease, and no one required oxygen support. There were consistently non-significant differences between antibody levels of those infected after the third dose relative to those non-infected (**Figure 3**). Regarding reactogenicity, adverse events were not systematically recorded in our study. However, none of our study participants declared an ICSR submission, evidence confirming the absence of serious adverse events in this study.

Discussion

This study evaluated the serologic response to a third BNT162b2 mRNA vaccine dose in a mixed cohort of immunocompromised patients. The main result of our study was that the third dose of vaccine allows boosting the humoral response to SARS-CoV-2 in this population. Indeed, the humoral response to the third homologous additional dose of BNT162b2 vaccine was found to be significantly higher (about 35 times) than the baseline immune status prior to the third vaccine.

All patients produced sufficient levels of anti-S IgG antibodies except one with lymphoma history. Similar trends were observed in studies where the third dose was administered in patients receiving hemodialysis or peritoneal dialysis.⁸

A significant number of vulnerable people enrolled in our study (n=20) reported a history of cancer. We observed a strong and effective humoral response to the third dose, even the ones with low titles before administration. Shapiro et al. found that among 88 patients with cancer who received booster vaccinations, 64% were seropositive prior to booster vaccination, and 36% seronegative and even those patients who received therapy within 30 days of booster vaccination had a statistically significant chance for seroconversion.⁹

Zeng et al. demonstrated that the diagnosis of a solid cancer *per se* does not appear to negatively impact the humoral immune response to booster-mediated protections against SARS-CoV-2 variants, including Omicron. They also examined the nAb titers against the Omicron, D614G, and Delta variants for patients with cancer who received a third dose of vaccine and overall, booster recipients exhibited dramatically increased nAb titers. Their results indicate a stronger and much broader neutralization even in the Omicron variant after the booster vaccination.¹⁰

In our study were included three patients with history of leukemia who showed a significant increase in the immune response after 3rd dose administration. Similarly, in a study conducted by Heirishanu et al. in patients with chronic lymphocytic leukemia who failed to achieve a humoral response after the standard 2-dose vaccination regimen, a significant immune response was observed to a third BNT162b2 mRNA COVID-19 vaccine.¹¹

Concerning transplant recipients, vaccination with a third dose elicited significantly higher antibody titers compared with the very low levels observed at baseline to four participants. Similarly, 44% of solid-organ transplant recipients who had been seronegative after 2 doses of BNT162b2 became seropositive after a third vaccine dose.¹² Likewise, Hod et al. found that a booster dose elicited a strong and effective humoral response in renal transplant recipients who were either seropositive or seronegative before the administration of the 3rd dose.¹³

54 patients with chronic autoimmune disease were involved in our study, who developed a significant higher immune response compared to that at baseline. These results demonstrate that a 3rd dose may be extremely useful, for the

prevention of severe disease, hospitalization and deaths of infections caused by SARS-CoV-2, in this patient group. This is of utmost importance since patients with autoimmune disease are more at risk of serious COVID-19 infections. Indeed, Papagoras et al. proved that the hospitalization and mortality rates were higher in unvaccinated (29% and 4%), than the fully vaccinated rheumatic patients (10% and 0%).¹⁴

In accordance with our study are the results of a recently published very interesting network meta-analysis which found that the effect of two dose mRNA vaccines is weaker in those who are immunocompromised than in those who are non-immunocompromised but a three dose mRNA regimen works comparably well in the non-immunocompromised and immunocompromised individuals. Further, that a three-dose regimen is similarly effective in all age groups, even in people over 65.¹⁵

Finally, in our study seven participants were infected with the Omicron variant (B.1.1.529), two to five months after the third dose. Owing to the large number of mutations in the spike protein,¹⁶ there is concern that this variant will exhibit substantial escape from vaccine-elicited immunity. Although data suggests that three doses of heterologous or homologous booster vaccination had a 25-100-fold-increase in neutralizing titers against Omicron variant, compared to two-dose vaccinations,¹⁷ recent studies demonstrate a decrease in the effectiveness of the 3rd dose after 10 weeks¹⁸ and that antibody titers diminish more rapidly in immunocompromised patients than healthy individuals¹⁹ while a study in Israel provided evidence for the effectiveness of a fourth vaccine dose in subjects having received a third dose more than 4 months earlier.²⁰

Limitations

Limitations of this study include a small and heterogeneous convenience sample and the absence of assays for neutralizing antibody, B-cell memory, and T-cell responses. Furthermore, measurement of antibody titers six months after the third dose is pending, however it has already been planned. These limitations may be addressed in further studies.

Conclusions

Overall, our findings verify the strong immunogenicity elicited by the 3rd dose of BNT162b2 vaccine in all categories of immunocompromised participants,

highlighting the importance of the third dose. Continued monitoring of vulnerable patient groups is of paramount importance for deciding the vaccination scheme for this population. Considering the predominance of omicron variants in the current period and the results of studies showing a decrease in the effectiveness of the 3rd dose after 10 weeks we highly recommend a fourth dose to this vulnerable population group.

References

1. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *The Lancet*. **2021**;397(10287):1819-29.
2. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N Engl J Med*. **2021**;385(24):e84-e84.
3. Deepak P, Kim W, Paley MA, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. *Ann Intern Med* **2021**. Nov;174(11):1572-1585
4. Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus *Leukemia*. **2020**;34(9):2354-2363
5. Tarhini et al. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. *J Infect Dis*. **2021** May 20;223(9):1522-1527
6. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. *Arthritis Rheumatol*. **2021**;73:e60-75
7. Brosh –Nissimiv et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. *Clinical Microbiology and Infection* 2021.27. **2021**. 1652e1657.
8. Bensouna, I.; Caudwell, V.; Kubab, S.; et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. *Am. J. Kidney Dis*. **2022**, 79, 185–192.e1.
9. Shapiro LC, Thakkar A, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. *Cancer Cell*. **2022** Jan 10;40(1):3-5.

10. Zeng C, Evans JP, Chakravarthy K, et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. *Cancer Cell*. **2022**; **40**(2):117–119.
11. Yair Herishanu, Galia Rahav., et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. *Blood* **2022**. 139 (5): 678–685.
12. Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. *N Engl J Med*. **2021**;385(7):661–662
13. Hod T, Ben-David et al. BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients. *Transpl Int*. **2022** Mar 21;35:10239.
14. Papagoras, C.; Fragoulis, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. *Ann. Rheum. Dis.* **2021**;0:1–4.
15. WY Au, PP Cheung. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. *BMJ* **2022**; 377 doi: <https://doi.org/10.1136/bmj-2022-069989> (Published 31 May 2022)
16. Wang L, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. *J Med Virol*. **2021**;1-6..
17. Julia Stowe, Ph.D., Nick Andrews, Ph.D., Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med*. April 21, 2022; 386:1532-1546
18. Iacobucci G. Covid-19: Fourth vaccine doses—who needs them and why? *BMJ* **2022**; 376:o30
19. Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. *Ann Rheum Dis*. **2021**.;80:1306–1311.
20. Yinon M. Bar-On, M.Sc., Yair Goldberg, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. *N Engl J Med*. May 5, **2022**; 386:1712-1720




Figure 1. Boxplots of antibody levels (logarithmic scale) of the 2 groups before and 4 weeks after the 3rd dose




Figure 2. Scatterplot matrix depicting the relationship between fold changes in IgG after the booster dose against the subjects' age and days between second and third dose. No significant relationships were found.




Figure 3. Boxplots of antibody levels (logarithmic scale) of subjects infected 2-6 months after the 3rd booster dose versus those not infected. No significant differences were observed.

Table 1. Geometric means of concentrations (GMC) and fold changes of anti SARS-CoV-2 Spike IgG antibodies before and 4 weeks after 3rd-dose administration between the 2 groups and between infected and not infected subjects after 3rd dose.

Group 1: cancer, lymphoma, leukemia, transplants. Group 2: autoimmune, type I diabetes, irritated bowel

Groups	GMC (95% CI) Before booster dose	GMC (95% CI) After booster dose	Fold Change	p-value
Group 1(n=31)	363.87 (185.38, 714.22)	12874.01 (9106.99, 18199.2)	35.38 (25.48, 49.13)	<0.001
Group 2 (n=54)	495.27 (365.98, 670.24)	17430.22 (14690.71, 20680.6)	35.19 (3.86, 40.14)	<0.001
p-value	0.338	0.079	0.903	
No-COVID after 3 rd dose(n=72)	437.38 (308.09, 620.93)	14802.39 (12312.52, 17795.76)	33.84 (28.66, 39.96)	<0.001
COVID after 3 rd dose(n=7)	573.53 (261.17, 1259.44)	23211.73 (11537.69, 46697.76)	40.47 (37.08, 44.18)	<0.001
p-value	0.643	0.151	0.631	
Female (n=46)	513.55 (343.81, 767.10)	15947.25 (12619.20, 20153.00)	31.33 (22.66, 43.32)	<0.001
Male (n=39)	370.87 (228.27, 602.57)	15195.57 (11930.26, 19354.59)	36.04 (26.17, 49.63)	<0.001
p-value	0.296	0.775	0.579	
Overall (n=85)	442.17 (325.40, 600.85)	15606.72 (13229.01, 18411.78)	35.30 (30.64, 40.65)	<0.001